Inactivation through promoter methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene, which impairs the ability to repair DNA damaged induced by alkylating agents such as TMZ [5], has been described as a relevant biomarker for clinical decision-making in glioblastoma treatment. Here, MGMT is linked to glioblastoma.